CEO Ben Lamm, who comes from a software background, believes his lack of formal biology training is a strength. It forces him to approach the immense challenge of de-extinction as a systems engineering problem, building the organization from first principles without the constraints of traditional academic or biotech thinking.

Colossal generates value not by selling resurrected animals but by spinning out valuable technology companies developed during its R&D, such as a computational biology platform. The long-term vision involves biodiversity credits rather than direct sales.

Colossal's AI spinoff, Astromech, is pioneering a new form of drug discovery. Instead of traditional methods, it uses AI to analyze evolutionary trends in animal genomes, identifying conserved regions that grant resistance to diseases like cancer (e.g., P53 protein in elephants) for application in human therapeutics.

To convince governments to protect ecosystems, Colossal Biosciences frames biodiversity not just as an environmental good, but as a source of economic value. Using the Gila monster's venom leading to the GLP-1 market as an example, they help nations underwrite and protect natural assets for their potential to create medical breakthroughs.

The ultimate convergence of AI and biology will be a predictive model of Earth's ecosystem. This "digital twin of nature" would allow humanity to understand the real-time consequences of decisions like building a data center or diverting a river, transforming environmental policy and conservation efforts with predictive power.

CEO Ben Lamb counters ethical criticism by arguing that humanity is already negatively "playing God" by causing mass extinction. He posits a moral obligation to use technology to reverse the damage we've caused, turning the common critique on its head.

Anti-extinction startup Colossal is leveraging high-profile clients like Tom Brady for pet cloning. This creates buzz and revenue, effectively funding long-term R&D with a luxury consumer service while its more ambitious projects (reviving mammoths) are still in development.

When raising for a "civilization tech" company, Colossal purposefully avoided investors seeking 4-5 year fund returns. They targeted patient capital from system-builders like Jim Breyer and Thomas Tull, who have experience backing foundational technologies like the internet and quantum computing and understand multi-decade horizons for creating new economies.

Colossal CEO Ben Lamb, a software entrepreneur with no biology background, approached top geneticist George Church seeking world-changing problems. His ability to build teams and secure capital, unconstrained by scientific dogma, was key to launching the ambitious de-extinction venture.